Title | Longitudinal Neuroimaging Analysis in Mild-Moderate Alzheimer's Disease Patients Treated with Plasma Exchange with 5% Human Albumin. |
Publication Type | Journal Article |
Year of Publication | 2018 |
Authors | Cuberas-Borrós, G, Roca, I, Boada, M, Tárraga, L, Hernandez, I, Buendia, M, Rubio, L, Torres, G, Bittini, Á, Guzmán-de-Villoria, JA, Pujadas, F, Torres, M, Núñez, L, Castell, J, Páez, A |
Journal | J Alzheimers Dis |
Volume | 61 |
Issue | 1 |
Pagination | 321-332 |
Date Published | 2018 |
ISSN | 1875-8908 |
Keywords | Aged, Aged, 80 and over, Alzheimer Disease, Female, Humans, Longitudinal Studies, Magnetic Resonance Imaging, Male, Middle Aged, Neuroimaging, Plasma Exchange, Serum Albumin, Human, Time Factors, Tomography, Emission-Computed, Single-Photon, Treatment Outcome |
Abstract | BACKGROUND: Recently, modifications of Aβ1-42 levels in CSF and plasma associated with improvement in memory and language functions have been observed in patients with mild-moderate Alzheimer's disease (AD) treated with plasma exchange (PE) with albumin replacement. OBJECTIVE: To detect structural and functional brain changes in PE-treated AD patients as part of a Phase II clinical trial. METHODS: Patients received between 3 and 18 PE with albumin (Albutein® 5%, Grifols) or sham-PE (controls) for 21 weeks (divided in one intensive and two maintenance periods) followed by 6-month follow-up. Brain perfusion assessed by SPECT scans using an automated software (NeuroGam®) and brain structural changes assessed by MRI were performed at weeks 0 (baseline), 21, and 44 (with additional SPECT at weeks 9 and 33). Statistical parametric mapping (voxel-based analysis, SPM) and Z-scores calculations were applied to investigate changes to baseline. RESULTS: 42 patients were recruited (39 evaluable; 37 analyzed: 18 PE-treated; 19 controls). There was a trend toward decreasing hippocampi and total intracranial volume for both patient groups during the study (p CONCLUSIONS: Mild-moderate AD patients showed decreased brain volume and impairment of brain perfusion as expected for the progression of the disease. PE-treatment with albumin replacement favored the stabilization of perfusion. |
DOI | 10.3233/JAD-170693 |
Alternate Journal | J. Alzheimers Dis. |
PubMed ID | 29154283 |
PubMed Central ID | PMC5734124 |